508 related articles for article (PubMed ID: 28870033)
1. [The expression and clinical significance of proprotein convertase subtilisin kexin 9 in rheumatoid arthritis].
Du Q; Yu XJ; Li HJ; Guan SQ; Zhang ZY; Mei YF
Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):655-659. PubMed ID: 28870033
[No Abstract] [Full Text] [Related]
2. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
[TBL] [Abstract][Full Text] [Related]
4. [Association between systemic inflammation and autoimmunity parameters and plasma lipid in patients with rheumatoid arthritis].
Xue C; Liu WL; Sun YH; Ding RJ; Hu DY
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):941-5. PubMed ID: 22321280
[TBL] [Abstract][Full Text] [Related]
5. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
[TBL] [Abstract][Full Text] [Related]
6. [Elevated level of serum PCSK9 in patients with systemic lupus erythematosus].
Fang C; Luo T; Chen X; Lin L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Jun; 34(6):541-545. PubMed ID: 30236208
[TBL] [Abstract][Full Text] [Related]
7. Proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism interacts with alcohol consumption to modulate serum lipid levels.
Aung LH; Yin RX; Wu DF; Cao XL; Hu XJ; Miao L
Int J Med Sci; 2013; 10(2):124-32. PubMed ID: 23329883
[TBL] [Abstract][Full Text] [Related]
8. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
Viney NJ; Yeang C; Yang X; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075
[TBL] [Abstract][Full Text] [Related]
9. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
Simonen P; Stenman UH; Gylling H
Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of PCSK9 and blood lipid in patients with sepsis].
Chen X; Huang X; Tian H; Kong G; Hu H; Lyu B; Liu X; Lu F; Shang Q; Hao D; Wang X; Wang T
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Jun; 34(6):614-619. PubMed ID: 35924517
[TBL] [Abstract][Full Text] [Related]
11. Effect of IL-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type-9 and Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients.
Ferraz-Amaro I; Hernández-Hernández MV; Tejera-Segura B; Delgado-Frías E; Macía-Díaz M; Machado JD; Diaz-González F
Horm Metab Res; 2019 Mar; 51(3):200-209. PubMed ID: 30695794
[TBL] [Abstract][Full Text] [Related]
12. Dietary high oleic canola oil supplemented with docosahexaenoic acid attenuates plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels in participants with cardiovascular disease risk: A randomized control trial.
Pu S; Rodríguez-Pérez C; Ramprasath VR; Segura-Carretero A; Jones PJ
Vascul Pharmacol; 2016 Dec; 87():60-65. PubMed ID: 27374222
[TBL] [Abstract][Full Text] [Related]
13. Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects.
Kwakernaak AJ; Lambert G; Muller Kobold AC; Dullaart RP
Thyroid; 2013 Feb; 23(2):166-72. PubMed ID: 23106476
[TBL] [Abstract][Full Text] [Related]
14. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.
Hamamura H; Adachi H; Enomoto M; Fukami A; Nakamura S; Nohara Y; Morikawa N; Sakaue A; Toyomasu K; Yamamoto M; Fukumoto Y
J Atheroscler Thromb; 2021 Apr; 28(4):329-337. PubMed ID: 32624555
[TBL] [Abstract][Full Text] [Related]
15. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
[TBL] [Abstract][Full Text] [Related]
16. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
[TBL] [Abstract][Full Text] [Related]
17. Several genetic polymorphisms interact with overweight/obesity to influence serum lipid levels.
Yin RX; Wu DF; Miao L; Aung LH; Cao XL; Yan TT; Long XJ; Liu WY; Zhang L; Li M
Cardiovasc Diabetol; 2012 Oct; 11():123. PubMed ID: 23039238
[TBL] [Abstract][Full Text] [Related]
18. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
[TBL] [Abstract][Full Text] [Related]
19. [Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis].
Ragino YI; Astrakova KS; Shakhtshneider EV; Stakhneva EM; Gafarov VV; Bogatyrev SN; Voevoda MI
Kardiologiia; 2017 Apr; 57(4):72-76. PubMed ID: 28762908
[TBL] [Abstract][Full Text] [Related]
20. Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome.
Wang M; Zhao D; Xu L; Guo W; Nie L; Lei Y; Long Y; Liu M; Wang Y; Zhang X; Zhang L; Li H; Zhang J; Yuan D; Yue L
Metabolism; 2019 May; 94():47-58. PubMed ID: 30768966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
